Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
Abstract Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP) previously under development as a lipid‐modifying agent that reduces LDL‐cholesterol and increases HDL‐cholesterol in hypercholesterolemic patients. Anacetrapib demonstrates a long terminal half‐life and accumulates in...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2019-12-01
|
| Edice: | Pharmacology Research & Perspectives |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/prp2.543 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
